ANI PHARMACEUTICALS INC
ANIP evidence brief
What we can confirm
- BioSniper Score:
- 6.7 / 10
- Market Cap:
- $1.61B
- Lead Asset:
- carbamazepine (Approved)
What it means
What to watch
Prepared research question
What matters most for ANIP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ANIP
ANI Pharmaceuticals Inc (ANIP) is a diversified pharmaceutical company operating through Rare Disease, Generics, and Brands segments, with a lead product in Purified Cortrophin® Gel and a growing ophthalmology franchise from the Alimera acquisition.
Key risk: Cortrophin Gel concentration risk
BioSniper Score
Based on 5 of 6 signals
Market Cap
$1.61B
Cash Runway
—
Lead Asset
carbamazepine (Approved)Next Catalyst
Patent_Expiry · Jan 12, 2028Financial data as of Jun 30, 2026.
Tracking 19 pipeline candidates · 3 clinical trials · 3 catalysts · 35 FDA decisions for ANI PHARMACEUTICALS INC.
ANI Pharmaceuticals Inc (ANIP) is a diversified pharmaceutical company operating through Rare Disease, Generics, and Brands segments, with a lead product in Purified Cortrophin® Gel and a growing ophthalmology franchise from the Alimera acquisition.
- Record net revenues of $883.4 million in 2025, representing 43.8% year-over-year growth [sec · filed 2026-04-09].
- Rare Disease portfolio generated $422.6 million in 2025 revenue, including $347.8 million from Cortrophin Gel (75.6% YoY growth) [sec · filed 2026-04-09].
- Acquired Alimera Sciences on September 16, 2024, adding ILUVIEN and YUTIQ franchises for diabetic macular edema and non-infectious uveitis [sec_mda · as of 2026-08-07].
- Cash & equivalents of $360.2M, total revenue $266.0M, net income $24.7M, shareholders' equity $597.2M, total debt $301.5M as of 2026-06-30 [sec].
- Phase 4 SYNCHRONICITY trial of fluocinolone acetonide intravitreal implant met both co-primary endpoints [news · published 2026-07-13].
What works
- Strong revenue growth trajectory: net revenues tripled since 2022, with adjusted non-GAAP EBITDA more than quadrupling over the same period [sec · filed 2026-04-09].
- Rare Disease franchise, led by Cortrophin Gel, is a high-growth driver with 75.6% year-over-year net sales growth in 2025 [sec · filed 2026-04-09].
- Diversified business model across Rare Disease, Generics, and Brands, supplemented by strategic acquisitions like Alimera Sciences [sec_mda · as of 2026-08-07].
- Positive Phase 4 clinical results for fluocinolone acetonide intravitreal implant support the ophthalmology franchise's potential [news · published 2026-07-13].
What to weigh
- High reliance on Cortrophin Gel for Rare Disease revenue; any supply or regulatory disruption could materially impact top-line growth [sec · filed 2026-04-09].
- Total debt of $301.5M as of 2026-06-30 represents a significant liability, though offset by $360.2M in cash [sec].
- Patent expirations for key products (e.g., fluocinolone acetonide NDAs in 2028) may open the door to generic competition [catalyst].
- Acquisition-driven growth strategy may require additional debt or equity financing, increasing financial risk [sec_mda · as of 2026-08-07].
From the filings
Quoted directly from source documents.
Record net revenues and strong growth
“we generated record net revenues of $883.4 million, representing 43.8% growth year-over-year”
SEC filings · April 9, 2026
Cortrophin Gel is the lead Rare Disease product
“our Rare Disease portfolio generated $422.6 million in revenue, including $347.8 million in net sales from our lead product Purified Cortrophin® Gel”
SEC filings · April 9, 2026
Alimera acquisition added ophthalmology franchise
“the Company acquired Alimera Sciences, Inc. ("Alimera"). In connection with the Merger, the Company added a growing and durable franchise, ILUVIEN (fluocinolon e acetonide intravitreal implant) 0.19 mg”
SEC MD&A · August 7, 2026
Phase 4 SYNCHRONICITY trial met endpoints
“positive topline data from its Phase 4, open-label, single-arm SYNCHRONICITY clinical trial of Fluocinolone Acetonide Intravitreal Implant”
News · July 13, 2026
Catalyst timeline
- 2028-01-12 · Patent_Expiry · FLUOCINOLONE ACETONIDE — NDA210331 — Patent expiry for a fluocinolone acetonide product; may open the door to generic competition.
- 2028-11-07 · Patent_Expiry · FLUOCINOLONE ACETONIDE — NDA201923 — Second patent expiry for a fluocinolone acetonide product; further generic risk.
- 2043-10-27 · Patent_Expiry · CORTICOTROPIN — NDA008975 — Long-dated patent expiry for corticotropin; no near-term generic threat.
Risks & what to watch (4)›
Key risks
- Cortrophin Gel concentration risk — Rare Disease revenue heavily depends on Cortrophin Gel; supply or regulatory issues could significantly impact financials [sec · filed 2026-04-09].
- Debt level — Total debt of $301.5M as of 2026-06-30, though offset by $360.2M cash, still represents a material obligation [sec].
- Patent expirations — Key fluocinolone acetonide patents expire in 2028, potentially allowing generic competition [catalyst].
- Acquisition financing risk — Future acquisitions may require additional debt or equity, increasing financial leverage and dilution risk [sec_mda · as of 2026-08-07].
What to watch
- Cortrophin Gel revenue trajectory and any supply chain developments [sec · filed 2026-04-09].
- Integration and market uptake of ILUVIEN and YUTIQ following the Alimera acquisition [sec_mda · as of 2026-08-07].
- Patent expirations in 2028 for fluocinolone acetonide products and potential generic entry [catalyst].
- Ability to sustain non-GAAP EPS growth of 15% as projected for FY26 [news · published 2026-04-04].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 10, 2026 · How we verify sources →
Run ANI PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ANI PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.50 · 4% dilution
Lead: Approved
19 candidates
3 upcoming, next in ~455d
0 buys · 16 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
277
Total value held
$1.76B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 2,747,492 | $211.3M |
| vanguard capital management llc | 823,064 | $63.3M |
| soleus capital management, l.p. | 820,243 | $63.1M |
| state street corp | 771,587 | $59.3M |
| tang capital management llc | 707,500 | $54.4M |
| goldentree asset management lp | 667,981 | $51.3M |
| deep track capital, lp | 600,000 | $46.1M |
| millennium management llc | 592,013 | $45.5M |
| arrowstreet capital, limited partnership | 564,360 | $43.4M |
| dimensional fund advisors lp | 531,190 | $40.8M |
Showing top 10 of 277 institutional holders of ANI PHARMACEUTICALS INC. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 19.0%
- Days to cover
- 10.8
- Shares short
- 3,562,734
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ANIP short interestGovernance
Frequently asked questions
What is the AI investment thesis for ANI PHARMACEUTICALS INC?
ANI Pharmaceuticals Inc (ANIP) is a diversified pharmaceutical company operating through Rare Disease, Generics, and Brands segments, with a lead product in Purified Cortrophin® Gel and a growing ophthalmology franchise from the Alimera acquisition.
What is ANI PHARMACEUTICALS INC's lead drug candidate?
ANI PHARMACEUTICALS INC's most advanced tracked candidate is carbamazepine (Approved).
What is ANI PHARMACEUTICALS INC's next catalyst?
ANI PHARMACEUTICALS INC's next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA210331" — expected January 12, 2028.
Who is the CEO of ANI PHARMACEUTICALS INC?
Mr. Nikhil Lalwani is the chief executive officer of ANI PHARMACEUTICALS INC (ANIP).
Where is ANI PHARMACEUTICALS INC headquartered?
ANI PHARMACEUTICALS INC (ANIP) is headquartered in Baudette, MN, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.